$BIAF News

bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry

BioAffinity Technologies Reports April CyPath Lung Diagnostic Unit Sales Up 300% YoY

bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY

bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate

bioAffinity Technologies shares are trading higher after the company announced a pilot study evaluating its tests for chronic obstructive pulmonary disease in collaboration with Brooke Army Medical Center.

bioAffinity Partners With U.S. Military Medical Center To Develop AI-Driven Diagnostics For Asthma And COPD

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

bioAffinity Technologies shares are trading higher after the company announced a year-over-year increase in its Q1 CyPath Lung Diagnostic unit sales.

bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

What's Going On With bioAffinity Technologies Stock Wednesday?

What's Going On With bioAffinity Stock Thursday?

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

Why Is bioAffinity Technologies Stock Surging Tuesday?

bioAffinity Technologies shares are trading higher after the company announced a new clinical case study that highlights the benefit of adding CyPath Lung, a noninvasive test for lung cancer, to the diagnostic pathway for a high-risk patient with multiple pulmonary nodules.

bioAffinity Technologies Releases New Clinical Case Study Highlighting Benefit Of Adding CyPath Lung To Diagnostic Pathway For High-Risk Patient With Multiple Pulmonary Nodules

bioAffinity Technologies Stock Cools Off After Strong Friday Rally - Here's Why

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth